

GALIEN FORUM 2012

TUESDAY OCTOBER 16, 2012

7:30AM - REGISTRATION

8:00AM - 3:30 PM

ALEXANDRIA CENTER™ FOR LIFE SCIENCE,
NEW YORK CITY

Apella™ Event Space at Alexandria Center™ (www.apella.com)
450 East 29th Street, 2nd Floor
(Between 1st Avenue And The East River)

GALIEN FORUM SPONSORS

PLATINUM



ORACLE®
HEALTH SCIENCES

SILVER

ONLY LYON



Proskauer >>

GALIEN FOUNDATION CORPORATE MEMBERS

LEADER

Deloitte.

Johnson & Johnson

Pfizer
New Medicines. New Hope.

ASSOCIATE

ACORDA
Pharmaceuticals

AstraZeneca
life inspiring ideas

biogen idec

DDb
Health Worldwide



REGENERON
science to medicine™

SJU SAINT JOSEPH'S UNIVERSITY
Erivan K. Haub School of Business
Executive Pharmaceutical Marketing MBA

MEDIA PARTNERS

FT
FINANCIAL
TIMES

BioPharm Insight
Leading Insight and Intelligence



Innovation to improve the Human Condition

www.galienfoundation.org

ALEXANDRIA CENTER FOR LIFE SCIENCE— NEW YORK CITY

Building Life Science Communities

Alexandria Center for Life Science – New York City fosters unique and innovative collaborations among New York City's world-renowned academic and medical institutions, leading scientific talent, sophisticated investment capital, together with the broad and diverse life science industry.

TO LEARN MORE,
PLEASE CONTACT:

Joel S. Marcus
Chairman/CEO
450 East 29th Street
New York, NY 10016
jmarcus@are.com

NYSE: ARE
www.are.com

It is our great pleasure to welcome you to the American Museum of Natural History as the Galien Foundation presents the 2012 Prix Galien USA Awards Ceremony.

We are pleased to join the Galien Foundation in applauding the innovative scientists who continue to pioneer both the medicines and strategies that are making a lasting, positive, and meaningful impact on communities around the world.

On behalf of Alexandria Real Estate Equities, Inc., we congratulate the recipient of this year's *Pro Bono Humanum Award*, Dr. Francis S. Collins. Dr. Collins' longstanding leadership at the NIH along with his exceptional contribution to the ethical implications of scientific research render him uniquely deserving of this prestigious award.



ALEXANDRIA.

MORNING PLENARY SESSIONS

8:00 AM

Welcome

P. Roy Vagelos, M.D., Committee Chairman, Prix Galien USA

Joel S. Marcus, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments

Neil de Crescenzo, SVP and General Manager, Oracle Health Sciences

8:15 AM

21st Century Science: Building Partnerships, Managing for Success

Guido Rasi, Executive Director, European Medicines Agency

John Castellani, President & Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA)

Moderator: Andrew Jack, Financial Times

9:15 AM

Panel: "Looking Back, Moving Forward"

Moderator: Roger Longman, CEO, Real Endpoints

Panelists: **Fred Hassan**, Chairman of the board and chief executive officer of Bausch & Lomb
P. Roy Vagelos, M.D., Committee Chairman, Prix Galien USA

A biopharma transformation is underway. Once an industry focusing on health conditions impacting tens of millions, it increasingly concentrates its research on disorders affecting far fewer patients with critical and costly conditions. Highly successful former CEOs discuss what needs to change about the kinds of organizations they used to run -- and the requirements for the leaders who will be running them tomorrow.

10:15 AM

Coffee Break

SIMULTANEOUS SESSION

1

10:30 AM

PANEL I

Addressing Big Data Challenges in Genomics and Personalized Healthcare

ORACLE
HEALTH SCIENCES

Moderator:

Kris Joshi, Ph.D., Global Vice President, Healthcare, Oracle Health Sciences

Panelists:

Jean-Pierre A. Kocher, Ph.D. Head, The Bioinformatics Core (BIC) of the Mayo Clinic

Martin Leach, Chief Information Officer, Broad Institute, MIT and Harvard

Nadeem Sarwar, MRPharmS Ph.D., Senior Director – Head, Population Research & Head, Cardiovascular Genetics, Pfizer

Scot Stevens, Chief Information Officer, UPMC CancerCenter & UPCI, Director Personalized Medicine Technology, UPMC

As the cost of genome sequencing has declined dramatically during the past years, a consumer driven genomics revolution is around the corner. This will have a profound impact on the prospects for personalized healthcare. However, gains in genome sequencing are only part of the journey toward personalized healthcare. The panel is in formation. This session will discuss and debate the opportunities and challenges in the quest for personalized healthcare.

Topics include:

- > How will the equation between the cost of genome sequencing and the cost of analysis be balanced?
- > How long will it be before genomic analysis is available to clinicians?
- > How will the patient manage his/her own genomic information?
- > What role will access to large public reference datasets play in accelerating personalized healthcare initiatives?

12:00 PM

Lunch Break

SIMULTANEOUS SESSION

2

10:30 AM

PANEL II

Infectious Diseases: A Global Healthcare Challenge



ALEXANDRIA.

Building the Future of Life Science™

Moderator:

Maria Freire, PhD,
President, Albert & Mary Lasker Foundation

Panelists:

Alice Dautry, PhD, *President, Institut Pasteur*
Julie L. Gerberding, MD, MPH, *President, Merck Vaccines, Merck & Co., Inc.;
Former Director, Centers for Disease Control and Prevention (CDC)*
Margaret Hamburg, MD, *Commissioner of Food and Drugs, U.S. Food and Drug Administration*
Lynn Marks, MD, *Senior Vice President, Projects, Clinical Platforms & Sciences, GlaxoSmithKline plc*

A global discussion of the challenges and opportunities facing the field of infectious diseases, today's panel will identify the field's most critical issues while discussing future strategies to accelerate the development of therapies to treat, diagnose and prevent infectious diseases ranging from HIV/AIDS, TB, Malaria and other important diseases.

12:00 PM

Lunch Break



STROSBERG, Arthur Donny scientist known as one of the first discoverers of a gene responsible for obesity, passed away on March 15th. At age 67, A.D. Strosberg was at the summit of an illustrious career, holding a permanent Professor chair at the University of Paris VII, a consultancy position for the Pasteur Institute and multiple Biotech companies, as well as a position at The Scripps Institute. Strosberg was also on the Board of Governors of Saint Mary's hospital.

A "self-made" man, Strosberg began his life in exile and ended it as internationally renowned in the scientific community. Born in 1945 in a Swiss refugee camp, his parents escaped persecution during the Holocaust by seeking sanctuary in the mountains. His mother came from a famous Marrano, Dutch-Portuguese family, the Lopes Cardozos, distantly related to the family of Judge Benjamin Cardozo. The rest of the family came from Poland and migrated to Belgium. Strosberg's grandparents and a large part of the family were murdered by the Nazis.

Prof. Strosberg was trained as a Dr. Sci. at the Free University of Brussels and did his post-doctoral fellowship at Massachusetts General Hospital in Boston. After serving at the Harvard Medical School as an Instructor, and later as a visiting Professor, he became Professor of Biochemistry and Immunology, first in Brussels, then in Paris. With

his teams, he published over 400 peer-reviewed, original scientific articles, several books and dozens of book chapters. He authored twenty-six issued patents of which several were licensed to pharmaceutical companies. Professor Strosberg has lectured and given talks in 25 countries.

Prof. Strosberg co-founded a number of biotechnology companies including Chemunex with the University of Paris; Incyte in California; Praecis, with M.I.T and BioRelix with Yale University. From 1998 to 2004 Prof. Strosberg was the Chairman and CEO of Hybrigenics, co-founded with the Pasteur Institute in 1998.

In 2005, Strosberg and his family relocated from Europe to West Palm Beach where he became Professor at The Scripps Research Institute. Here, Strosberg contributed his ingenuity and brilliance to research on Hepatitis C.

Strosberg's Scripps team was recently awarded \$1.5 million by the National Institutes of Health to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV), the cause of AIDS. At his passing, Prof. Strosberg was just weeks away from receiving his American citizenship; a milestone he proudly anticipated. He was involved in the community and supported many charities. Brilliant, decent, remarkable, loving and joyful were the words mentioned most often when people talk about Donny. He is survived by beloved wife of 46 years, Eliane, and his children Serge, Muriel and his grandson Joshua.

SIMULTANEOUS SESSION

3

10:30 AM

PANEL III

Alzheimer's Innovation and the White House 2025 Mandate: What Will it Take to Find a Treatment?

Moderator:

Michael Rosenblatt, M.D., *Executive Vice President and Chief Medical Officer, Merck*

Panelists:

Meryl Comer, *President, Geoffrey Beene Foundation Alzheimer's Initiative*

Stephen Hume, Psy.D., *Clinician and patient with early onset Alzheimer's disease*

Russell Katz, M.D., *Director, Division of Neurology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration*

William Potter, M.D., Ph.D., *Senior Advisor, National Institute of Mental Health*


Dennis Selkoe, M.D., *Co-Director, Center for Neurologic Diseases, Brigham and Women's Hospital, and Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School*

William Thies, Ph.D., *Chief Medical and Scientific Officer, Alzheimer's Association*

A conversation with government, industry and advocacy leaders on Alzheimer's innovation and the White House 2025 mandate to develop an elective medicine.

12:00 PM

Lunch Break



PLENARY SESSION

12:30 PM

Ethics of Innovation

Under the auspices of the Elie Wiesel Foundation for Humanity

Chair:

Professor Elie Wiesel, Author and Peace Nobel Prize Laureate

Panelists:

Margaret Hamburg, M.D., Commissioner, U.S. Food and Drug Administration**Guido Rasi**, Executive Director, European Medicines Agency

Moderator:

William Looney, Editorial Director Pharmaceutical Executive Magazine

Innovation in biomedicines is essential to maintaining progress in global public health. This panel will review key issues in the science and policy of innovation, including the roles of government, the private sector, academia and other stakeholders in fostering new medical advances; prioritizing current and future areas of unmet medical need; establishing an appropriate regulatory balance between drug risk and benefit; promoting access, affordability and the human right to health; and defining our collective moral responsibilities to the patient, through the ethical conduct of human clinical trials, safe use of new health technologies, and preventing the misrepresentation of science for political or ideological means.

PANEL 4

2:00 PM

The changing face of Chinese healthcare

Moderator:

Kimberly Ha, Global Editor, Biopharm Insight

Panelists:

Les Funtleyder, Fund Manager, Polliwog**R.T. (Terry) Hisey**, Vice Chairman & US Life Sciences Leader, Deloitte LLP**William Kridel**, Partner, Ferghana Partners**Anthony Sun**, Partner, Aisling Capital

This session will discuss and debate the opportunities and challenges with investing in the Chinese healthcare market. How do companies navigate doing business in this high growth, emerging market?

Discussion topics:

What are the major trends and issues companies need to be aware of before doing business in China?

What is the SFDA product approval process in China?

What to look for when selecting a CRO partner?

Current trends in the Chinese healthcare market?

Deloitte.
BioPharm Insight
 Leading Insight and Intelligence

PANEL 5

Art and Science: From Anatomy to Genetics

Moderator:

Eliane Strosberg, MD., PhD.*

This presentation will focus on the intersections between art and medicine, from anatomy to genetics. The dialogue between Art and Science has powerfully shaped both endeavors since antiquity and is increasingly recognized as a major driving force of future education at the highest level.

* Eliane Strosberg holds an MD and a PhD from Brussels University and was a Research Fellow at Harvard.

She held several international management positions in American consulting firms for the chemical and pharmaceutical industries.

In addition, she received training in art history at the Brussels Free University and worked in the research laboratory of the Boston Museum of Fine Arts. She has devoted a lot of time to research the connections between Art and Science which resulted in a book first published by UNESCO that evolved into a broad cultural educational program. It was translated in several languages and was published in the USA by Abbeville, Inc.

Her second book, *Human Expressionism*, tackles the question of art and religion. The book served as the catalogue for a widely acclaimed exhibition in France and was selected by the Art Books Fair at the Pompidou Center in Paris. The updated American edition was first presented at the NY Public Library.

Oracle congratulates the candidates
of the 2012 Prix Galien USA
New York, October 16, 2012



Proudly supporting the Prix Galien USA since 2008



Neil de Crescenzo, *Senior Vice President and General Manager, Oracle Health Sciences Global Business Unit* presenting the Award for the best pharmaceutical agent to Doctor David Epstein, Chief Operating officer of Novartis Pharmaceuticals Corporation, for Gleevec in the Presence of Pr Bengt Samuelsson (left), *Nobel Laureate and Committee Member of Prix Galien USA*, at the Prix Galien Awards ceremony in 2009.

ORACLE
HEALTH SCIENCES

PRIX GALIEN USA 2012 NEW YORK CITY



www.galienfoundation.org

Hollywood has the Oscars Biopharma has the Prix Galien

Worldwide the Prix Galien is regarded as the equivalent of the Nobel Prize for the biopharmaceutical industry. It is without question pharma's proudest night.

Final candidates for the Prix Galien USA 2012 Awards are:

Category: Best Biotechnology Product

Biogen Idec - TYSABRI®
Bristol-Myers Squibb - YERVOY™
GlaxoSmithKline - ARZERRA®
MedImmune/AstraZeneca - FLUMIST® QUADRIVALENT
Merck - ZOSTAVAX®
Regeneron Pharmaceuticals - EYLEA®
Sanofi Pasteur - FLUZONE®
Shire - VPRIV®
Shire - FIRAZYR®

Category: Best Medical Technology Product

Abbott - XIENCE V®
Berlin Heart - EXCOR®
Edwards Lifesciences - SAPIEN
Medtronic - Melody®
Novocure - NovoTTF™
Unilife - Unifill®
VisionCare Ophthalmic Technologies - CentraSight®

Category: Best Pharmaceutical Agent

Acorda Therapeutics - AMPYRA®
AstraZeneca - CAPRELSA®
Celgene Corporation - VIDAZA®
Roche/Genentech and Plexxikon - ZELBORAF®
GlaxoSmithKline - POTIGA™
GlaxoSmithKline - VOTRIENT®
Janssen - INTELENCE®
Janssen - XARELTO®
Janssen - ZYTIGA®
Merck - VICTRELIS®
Novartis - AFINITOR®
Optimer Pharmaceuticals - DIFICID®
Pfizer - XALKORI®
Purdue Pharma - OxyContin®
Theravance - VIBATIV®
UCB - VIMPAT®
Vertex Pharmaceuticals - INCIVEK®



The Galien Foundation
60 Broad Street, Suite 3502 KVB
New York, NY 10004
Tel 212 685 1592
www.galienfoundation.org

And the winners are...

Rendez-vous tonight at the
American Museum of Natural History
New York City